Acylcarnitine profile analysis

Genetics in Medicine

Volumn 10, Issue 2, 2008, Pages 151-156

  Rinaldo, Piero ^a   Cowan, Tina M ^b   Matern, Dietrich ^a  

^a Mayo Clinic   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acylcarnitine profile; Clinical genetic testing; Inborn errors of metabolism; Tandem mass spectrometry; Technical standards and guidelines

Indexed keywords

ACYLCARNITINE;

CLINICAL LABORATORY; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC SERVICE; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; INCIDENCE; MEDICAL EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PROTEIN DEFICIENCY; QUALITY CONTROL; REVIEW;

BIOLOGICAL MARKERS; CARNITINE; GENES, RECESSIVE; GENETICS, MEDICAL; HUMANS; METABOLISM, INBORN ERRORS; PREVALENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 39449083613     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181614289     Document Type: Review

References (30)

1. Rinaldo P, Hahn SH, Matern D. Inborn errors of amino acid, organic acid, and fatty acid metabolism. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed. Philadelphia: WB Saunders, 2005:2207-2247.
2. Matern D. Acylcarnitine analysis. In: Blau N, Duran M, Gibson KM, editors. Laboratory guide to the methods in biochemical genetics. Berlin: Springer. In press.
3. Sweetman L, Millington DS, Therrell BL, Hannon WH, et al. Naming and counting disorders (conditions) included in newborn screening panels. Pediatrics 2006;17(5 Pt 2):S308-S314.
4. Chace DH. Mass spectrometry in the clinical laboratory. Chem Rev 2001;101:445-477.
5. Millington DS. Tandem mass spectrometry in clinical diagnosis. In: Blau N, Duran M, Blaskovics ME, Gibson KM, editors. Physician's guide to the laboratory diagnosis of metabolic diseases, 2nd ed. Berlin: Springer, 2003:57-75.
6. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005;38:296-309.
7. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol 2002;64:16.1-26.
8. Cuthbert CD, Tortorelli S, Ensenauer R, Rinaldo P, Matern D. Inherited abnormalities in mitochondrial fatty acid oxidation. In: Walker WA, Goulet OJ, Kleinman RE, Sanderson IR, et al, editors. Walker's pediatric gastrointestinal disease, 4th ed. Hamilton, Ontario: BC Decker, 2004:1287-1304.
9. Olpin SE. Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab 2005;51:289-306.
10. Blau N, Duran M, Blaskovics ME, Gibson KM, editors. Physician's guide to the laboratory diagnosis of metabolic diseases, 3nd ed. Berlin: Springer, 2006.
11. Rinaldo P. Organic acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory guide to the methods in biochemical genetics. Berlin: Springer. In press.
12. Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, et al. Newborn screening: Toward a uniform screening panel and system [main report]. Genet Med 2006;8(Suppl):12S-252S.
13. Ofman R, Ruiter JP, Feenstra M, Duran M, et al. 2-Methyl-3- hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am J Hum Genet 2003;72:1300 -1307.
14. Tortorelli S, Hahn SH, Cowan TM, Brewster TG et al. The urinary excretion of glutarylcarnitine is an informative tool in the biochemical diagnosis of glutaric acidemia type I. Mol Genet Metab 2005;84:137-143.
15. Oglesbee D, He M, Majumder N, Vockley J, et al. Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genet Med 2007;9:108-116.
16. Shen JJ, Matern D, Millington DS, Hillman S, et al. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit Metab Dis 2000;23:27-44.
17. Roe DS, Yang BZ, Vianey-Saban C, Struys E, et al. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. Mol Genet Metab 2006;87:40-47.
18. van Vlies N, Tian L, Overmars H, Bootsma AH, et al. Characterization of carnitine and fatty acid metabolism in the long-chain acyl-CoA dehydrogenase-deficient mouse. Biochem J 2005;387:185-193.
19. Chace DH, DiPerna JC, Mitchell BL, Sgroi B, et al. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 2001;47:1166-1182.
20. Rashed MS, Ozand PT, Bennett MJ, Barnard JJ, et al. Diagnosis of inborn errors of metabolism in sudden death cases by acylcarnitine analysis of postmortem bile. Clin Chem 1995;41:1109-1114.
21. Rinaldo P, Studinski A, Matern D. Prenatal diagnosis of disorders of fatty acid transport and mitochondrial oxidation. Prenat Diagn 2001;21:52-54.
22. Malvagia S, La Marca G, Casetta B, Gasperini S, et al. Falsely elevated C4-carnitine as expression of glutamate formiminotransferase deficiency in tandem mass spectrometry newborn screening. J Mass Spectrom 2006;41:263-265.
23. Westgard JO, Klee GG. Quality Management. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed. Philadelphia: WB Saunders, 2005:485-429.
24. CAP/ACMG Biochemical and Molecular Genetics Resource Committee. Committees and leadership. Available at: http://www.cap.org/
25. European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism (ERNDIM). Available at: http://www.erndimqa.nl/
26. Abdenur JE, Chamoles NA, Guinle AE, Schenone AB et al. Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J Inherit Metab Dis 1998;21:624-630.
27. Vianey-Saban C, Boyer S, Levrat V, Cheillan D, et al. Interference of Cefotaxime in plasma acylcarnitine profile mimicking an increase of 3-hydroxypalmitoleylcarnitine (C16:1-OH) using butyl esters. J Inherit Metab Dis 2004;27(Suppl 1):94.
28. Magera MJ, Hahn S, Tortorelli S, Rinaldo P, Matern D. Dextrose - an artifact detectable by newborn screening as a butylated acylcarnitine. J Inherit Metab Dis 2005;28(Suppl 1):1.
29. Iacobazzi V, Pasquali M, Singh R, Matern D, et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet 2004;126A:150-155.
30. Grier RE, Gahl WA, Cowan T, Bernardini I, et al. Revised sections F7.5 (quantitative amino acid analysis) and F7.6 (qualitative amino acid analysis): American College of Medical Genetics Standards and Guidelines for Clin Genet Laboratories, 2003. Genet Med 2004;6:66-68.